PMID- 32394732 OWN - NLM STAT- MEDLINE DCOM- 20211015 LR - 20211015 IS - 1460-2202 (Electronic) IS - 0271-3683 (Linking) VI - 45 IP - 12 DP - 2020 Dec TI - Optical Coherence Tomography Angiography of Inflammatory Choroidal Neovascularization Early Response after Anti-VEGF Treatment. PG - 1556-1562 LID - 10.1080/02713683.2020.1767790 [doi] AB - Purpose: To describe the optical coherence tomography angiography (OCTA) features of active inflammatory choroidal neovascularization (CNV) and characterize the early responses of anti-vascular endothelial growth factor (VEGF) treatment for inflammatory CNV. Methods: OCT angiography images of inflammatory CNV were acquired and analyzed using the RTVue XR Avanti with AngioVue at baseline as well as fluorescein angiography and spectral-domain optical coherence tomography (SD-OCT). OCTA scans were sequentially obtained 1 day before treatment, 1 day, 7 days, 14 days, and 30 days after anti-VEGF injection. Changes of the selected area and flow area of CNV on OCTA were measured along with those of the central macular thickness (CMT) on corresponding SD-OCT. Results: 19 eyes of 18 uveitic patients (mean age: 36.83 +/- 10.05 years) presenting with active CNV were included in the prospective case series. The OCTA showed a 100% sensitivity for inflammatory CNV detection in 23 of 23 CNV lesions, revealing prevailing two neovascular phenotypes: vascular loops and intertwined nets. After anti-VEGF injection, as early as the 1-day follow-up, the mean selected area and the mean flow area of inflammatory CNV on OCTA were significantly reduced (both P < .05) while the average CMT on SD-OCT did not change until the 7-day follow-up. OCTA was able to detect the reincrease of capillary density and vessel size predominantly in the second phenotype 14-30 days after anti-VEGF injection. Conclusions: OCTA not only allows for noninvasive detection of inflammatory CNV with a high sensitivity but also facilitates its sequential observation after anti-VEGF treatment. The treatment outcomes are observable at day 1 post treatment. OCTA may be a useful tool for diagnosing inflammatory CNV and evaluating the early response to anti-VEGF treatment. FAU - Tang, Wenyi AU - Tang W AD - Department of Ophthalmology, Eye and ENT Hospital of Fudan University , Shanghai, China. FAU - Guo, Jingli AU - Guo J AD - Department of Ophthalmology, Eye and ENT Hospital of Fudan University , Shanghai, China. FAU - Liu, Wei AU - Liu W AD - Department of Ophthalmology, Eye and ENT Hospital of Fudan University , Shanghai, China. FAU - Xu, Gezhi AU - Xu G AD - Department of Ophthalmology, Eye and ENT Hospital of Fudan University , Shanghai, China. AD - Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University , Shanghai, China. AD - NHC Key Laboratory of Myopia, Laboratory of Myopia, Fudan University, Chinese Academy of Medical Sciences , Shanghai, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200522 PL - England TA - Curr Eye Res JT - Current eye research JID - 8104312 RN - 0 (Angiogenesis Inhibitors) RN - 0 (VEGFA protein, human) RN - 0 (Vascular Endothelial Growth Factor A) SB - IM MH - Adult MH - Angiogenesis Inhibitors/*therapeutic use MH - Choroidal Neovascularization/*diagnosis/drug therapy/physiopathology MH - Female MH - *Fluorescein Angiography MH - Humans MH - Inflammation/*diagnosis/drug therapy/physiopathology MH - Intravitreal Injections MH - Male MH - Middle Aged MH - Prospective Studies MH - *Tomography, Optical Coherence MH - Vascular Endothelial Growth Factor A/antagonists & inhibitors MH - Visual Acuity/physiology OTO - NOTNLM OT - Optical coherence tomography angiography OT - anti-VEGF treatment OT - early response OT - inflammatory choroidal neovascularization OT - uveitis EDAT- 2020/05/13 06:00 MHDA- 2021/10/16 06:00 CRDT- 2020/05/13 06:00 PHST- 2020/05/13 06:00 [pubmed] PHST- 2021/10/16 06:00 [medline] PHST- 2020/05/13 06:00 [entrez] AID - 10.1080/02713683.2020.1767790 [doi] PST - ppublish SO - Curr Eye Res. 2020 Dec;45(12):1556-1562. doi: 10.1080/02713683.2020.1767790. Epub 2020 May 22.